News

PipelineReview.com33m
Phase III Clinical Study with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan Did Not Meet Its Primary Endpoint
I Taiho Pharmaceutical Co., Ltd. announced that the results of a phase III, randomized, placebo-controlled, double-blind and open-label, ...
PipelineReview.com36m
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
HYOGO, Japan I July 8, 2025 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, ...